Brain and Gut Responses to Intragastric Administration of FODMAPs in Healthy Subjects and Patients With Irritable Bowel Syndrome

Irritable Bowel Syndrome Clinical Trial

— FODMAPs  

Official title:

Brain and Gut Responses to Intragastric Administration of FODMAPs in Healthy Subjects and Patients With Irritable Bowel Syndrome

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT04283487
• Other study ID #: FODMAP2
• Status: Completed
• Phase: N/A
• Start date: February 22, 2018
• Est. completion date: August 10, 2019

Study information

• Verified date: May 2021
• Source: Universitaire Ziekenhuizen Leuven
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

Low fermentable oligo-, di- and monosaccharides and polyols (FODMAPs) diet is taken as a possible strategy to improve symptoms in IBS patients. However, the gut-brain signalling mechanisms underlying this observation remain poorly understood. In this study, the investigators aim to study the brain mechanisms underlying the effect of intragastric administration of one specific FODMAP (fructans) on gastrointestinal and non- gastrointestinal symptom responses, changes in gut physiology(morphology of the gut, water content and intestinal motility), and to relate the findings to changes in gastrointestinal peptides. Intragastric administration of three different solutions will be given after an overnight fast: one FODMAP solution (fructans), a positive control (glucose) and a negative control (saline). The whole procedure consists of a functional magnetic resonance imaging (fMRI) and abdominal MRI examination, and will take approximately four hours. The participants will undergo the fMRI for one hour for assessing brain activity, during which blood samples will be collected. The abdominal MRI will be performed at 1-hour interval for three hours to assess pre and post stimulated changes in gut physiology, specifically the morphology of the gut water content and pan-intestinal motility. During the whole procedure, questionnaires for assessing the gastrointestinal symptoms and emotional state will be collected. The investigators hypothesise that fructans induce distension and increased sensations of pain, cramps and flatulence in the IBS group more than the HC. Furthermore, this will be associated with increased activation of pain-responsive brain regions in IBS compared to HC, which will be mediated by differential changes in gut peptide levels (↓ in orexigenic and ↑ in anorexigenic hormones).

Description:

In this study, the investigators aim to study the brain mechanisms underlying the effect of intragastric administration of one specific FODMAP (fructans) on gastrointestinal and non- gastrointestinal symptom responses, changes in gut physiology(morphology of the gut, water content and intestinal motility), and to relate the findings to changes in gastrointestinal peptides.

This is a randomised, double-blinded, crossover study. Eligible participants will come three times to the clinic after an overnight fast, for intragastric infusion of fructans (40g in 500 ml water), glucose(40g in 500ml water) or saline(0.9% 500ml normal saline). The infusions will be given in counterbalanced order and with a washout period of at least one week. Participants and investigators will be blinded to the nature of the test solution, which will be made by a colleague unrelated to the study. The order of the test solutions will be determined by a computer-generated list. All participants will be asked to follow the low FODMAP diet for the 24 hours prior to each study day. Participants will be asked to record their food intake during the day to check their FODMAP intakes were reduced.

To begin, the participants will have a nasogastric feeding tube placed and an intravenous cannula inserted in the non-dominant arm to facilitate repeated blood sampling. Fifteen minutes later, they will enter the MR scanner for a 5 minute adaptation period. Participants will complete visual analogue scales (VAS) on appetite-related sensations and GI symptoms and blood samples will be collected for gut peptide analysis. Current emotional state will be rated before and after scanning using the PANAS, and during scanning using the POMS. The abdominal MRI scan will begin after the adaption period and will take 10 minutes. Hereafter, brain scanning will be performed, starting with a baseline brain scanning period of 10 minutes. After the baseline scanning, 500 mL of one of the three solutions will be infused as the functional brain imaging begins (and continues for 50 minutes). The VAS ratings will be collected every 10 minutes and blood samples will be collected every 20 minutes for measuring of ghrelin, CCK, GLP-1, motilin, and PYY, insulin and glucose throughout the scan. At 60 minutes post-infusion, a 10 minute abdominal scan will be acquired. After that, the subject leaves the scanner and the catheter will be removed. The subject will remain at the facility for a 2 hour follow-up during which the VAS ratings will be collected every 30 minutes and an abdominal MRI will be performed at 120 minutes post infusion. After the last abdominal MRI scan is performed, the infusion tube will be removed and the participant can go home.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 28
• Est. completion date: August 10, 2019
• Est. primary completion date: August 10, 2019
• Accepts healthy volunteers: Accepts Healthy Volunteers
• Gender: Female
• Age group: 18 Years to 55 Years

Eligibility

Healthy volunteers:

Inclusion Criteria:

• No symptoms or history of gastrointestinal disease or disorder, other significant diseases

• Female

• Age 18 - 55 years

• Body Mass Index (BMI) of 19 - 28 kg/m2

• Stable body weight for at least 3 months prior to the start of the study

• Right-handed or ambi-dexter

Exclusion Criteria:

• Medical

• Abdominal or thoracic surgery. Exception: appendectomy

• Gastrointestinal, endocrine or neurological diseases

• Cardiovascular, respiratory, renal or urinary diseases

• Hypertension

• Food or drug allergies

• Anemia Psychiatric disorders

• Eating disorders

• Depressive disorders

• Anxiety disorders

• Psychotic disorders Medication use

• No regular medication affecting CNS or GI system (oral contraception accepted) Other

• Conditions that can interfere with functional magnetic resonance imaging (fMRI), e.g. cochlear implants, metal fragments or metal implants in the body, pacemaker, neural stimulator, …

• No history of cannabis use or any other drug of abuse for at least 12 months prior to the study

• Alcohol abuse (more than 14 units for woman per week)

• People who show abnormal eating behavior or have followed a gluten-free or low-FODMAP diet previously

• Pregnant or breastfeeding women

• Claustrophobia

IBS patients:

Inclusion Criteria:

• Meet the Rome IV criteria for irritable bowel syndrome (IBS)

• Patient has IBS of any subtype

• Female

• Age 18 - 55 years

• Body Mass Index (BMI) of 19 - 28 kg/m2

• Stable body weight for at least 3 months prior to the start of the study

• Right-handed or ambi-dexter

Exclusion Criteria:

General exclusion criteria for all subjects:

Medical

• Abdominal or thoracic surgery. Exception: appendectomy

• Gastrointestinal, endocrine or neurological diseases

• Cardiovascular, respiratory, renal or urinary diseases

• Hypertension

• Food or drug allergies

• Anemia Psychiatric disorders

• Eating disorders

• Depressive disorders

• Anxiety disorders

• Psychotic disorders Medication use

• No regular medication affecting CNS or GI system (oral contraception accepted)

Other

• Conditions that can interfere with functional magnetic resonance imaging (fMRI), e.g. cochlear implants, metal fragments or metal implants in the body, pacemaker, neural stimulator, …

• No history of cannabis use or any other drug of abuse for at least 12 months prior to the study

• Alcohol abuse (more than 14 units of alcohol per week)

• People who show abnormal eating behavior, or have followed a gluten-free or low-FODMAP diet previously

• Pregnant or breastfeeding women

• Claustrophobia

Related Conditions & MeSH terms

• Irritable Bowel Syndrome
• Syndrome

Intervention

Dietary Supplement:
• Fructans
500ml 0.9% normal saline containing 40g fructans
• Glucose
500ml 0.9% normal saline containing 40g glucose
• Saline
500ml 0.9% normal saline

Locations

Country	Name	City	State
Belgium	KU Leuven	Leuven

Sponsors (1)

Lead Sponsor	Collaborator
Universitaire Ziekenhuizen Leuven

Country where clinical trial is conducted

Belgium, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Change in brain activation patterns measured by fMRI	change in blood oxygenation level dependent (BOLD) signal by fMRI	-10 min to 50 min
Secondary	Change in gastrointestinal symptom scores measured by VAS	bloating, nausea, cramps, flatulence and abdominal pain	-30 min to 180 min
Secondary	Change in state emotion score measured by validated questionnaire	emotion score measured by POMS	-30 min to 180 min
Secondary	Change in state emotion score measured by validated questionnaire	emotion score measured by PANAS	-30 min to 180 min
Secondary	Change in plasma levels of gut peptides	Plasma levels of ghrelin	-20 min to 60 min
Secondary	Change in plasma levels of gut peptides	Plasma levels of CCK	-20 min to 60 min
Secondary	Change in plasma levels of gut peptides	Plasma levels of GLP-1	-20 min to 60 min
Secondary	Change in plasma levels of gut peptides	Plasma levels of motilin	-20 min to 60 min
Secondary	Change in plasma levels of gut peptides	Plasma levels of PYY	-20 min to 60 min
Secondary	Change in plasma levels of gut peptides	Plasma levels of insulin	-20 min to 60 min
Secondary	Change in plasma levels of gut peptides	Plasma levels of glucose	-20 min to 60 min
Secondary	Change in gut physiology measured by abdominal MRI	Gastric emptying and accommodation, antral and small bowel motility, water and gas content measured by abdominal MRI	-20 min to 180 min